logo

Biotechnology News

Share
Swiss drug major Roche (RHHBY) announced Wednesday that the European Commission has approved Tecentriq (atezolizumab) for people with specific type of lung cancer. Tecentriq has been approved as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer or NSCLC whose...
farxiga may03 British drug major AstraZeneca's Farxiga (dapagliflozin) oral tablets can now be used in the United States to treat chronic kidney disease regardless of diabetes status. The U.S. Food and Drug Administration approved Farxiga meant to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
cigarettes april30 The U.S. Food and Drug Administration said it plans to ban menthol cigarettes and flavored cigars to significantly reduce disease and death from using combusted tobacco products, the major cause of preventable death in the U.S. The regulator said it is advancing two tobacco product standards, which will be issued within the next year to ban menthol as a characterizing flavor in cigarettes.
Read More
Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Biotechnology company Novavax, Inc. (NVAX) announced Thursday that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture...
pfizer may06 Covid vaccine developers Pfizer Inc. and BioNTech SE agreed to provide their vaccine doses to all those participating in the Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021. The companies have signed a Memorandum of Understanding or MoU with the International Olympic Committee or IOC to donate their COVID-19 vaccine to the participating athletes...
Read More

fritolay may07

Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses.

hershey may07

Hershey Co. is recalling a single lot of Hershey's Chocolate Shell Topping citing the possible presence of undeclared almonds, a known allergen, the U.S. Food and Drug Administration announced. The recall involves Chocolate Shell Topping in a 7.25-oz. (205g) bottle with UPC (346000). The products were shipped nationwide between April 15 and May 3, 2021 and bear the product code 25JSAS1.

cytosport may04

CytoSport, Inc. is recalling specific lots of Evolve Protein Shakes citing the possible presence of undeclared soy, an allergen, the U.S. Food and Drug Administration said. The recall involves Evolve Double Chocolate Protein Shake with MFG date of 12/31/2020 and 1/1/2021; and Evolve Vanilla Bean Protein Shake with MFG date of 12/30/2020 and 1/25/2021.

acella fda 050321

Acella Pharmaceuticals, LLC recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to sub potency, the U.S. Food and Drug Administration said in a statement. The company is recalling 35 commercial lots and three sample lots, including four lots of 15-mg, three lots of 30-mg, 11 lots of 60-mg, seven lots of 90-mg and ten lots of 120-mg of NP Thyroid.

Read More
Results Date Company Name Ticker Event Indication Outcome
2H 2021 Aridis Pharmaceuticals Inc ARDS Data from Phase IIa trial of AR-501 Cystic fibrosis
2H 2021 Aridis Pharmaceuticals Inc ARDS Top-line data from phase III pivotal trial of AR-301 Acute pneumonia caused by S. aureus infection
2H 2021 PhaseBio Pharmaceuticals Inc PHAS Results from Phase 2b clinical trial of PB1046 Pulmonary Arterial Hypertension
2H 2021 Summit Therapeutics plc SMMT Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 1) C. difficile infection
2H 2021 Summit Therapeutics plc SMMT Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 2) C. difficile infection
Read More
Given the rising number of daily coronavirus cases in some countries, the emergence of new variants, and waning immunity, it is for sure that COVID-19 will be an ongoing global public health concern. As of this writing, 155.3 million cases have been reported across the world, with the death tally crossing 3.24 million.
Read More
A new report by the Centers for Disease Control and Prevention, or CDC, has projected a sharp decline in coronavirus cases in the United States by July, and an even faster decline if more people get vaccinated sooner. The promising news appears in an article that CDC published in its Morbidity and Mortality Weekly Report that provides some insights using data and evidence to show various scenari
47325 new coronavirus cases were reported in the United States on Thursday, taking the national total to 33,369,192. The weekly average of daily infection is 45081. 818 new deaths were reported on the same day. With this, the COVID death toll in the U.S. increased to 594,006, according to the latest data from Johns Hopkins University. The 7-day average of COVID deaths is 693. 122 deaths were rep
Read More
Four novel drugs were approved by the FDA in March taking the tally of new drug approvals in the first quarter of this year to 14. Let's take a look at what's in store for April 2021.
The Food and Drug Administration approved four new drugs last month. In the year 2020, 104 new drugs were approved by the FDA. Now, let us take a look at the new drugs approved by the regulator in January 2021.
Read More
Shares of Ayala Pharmaceuticals Inc. (AYLA) are off 65% from their 52-week high of $28.68, recorded in February of this year, and trade around $10.
Shares of Zentalis Pharmaceuticals Inc. (ZNTL) which touched an all-time of $61.29 on Dec.20, 2020, have since erased 20%, and are trading around $43 currently.
Read More